Clinical Trial Update: The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gevokizumab in corticosteroid-resistant autoimmune inner ear disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Inner Ear Disease

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: XOMA (US) LLC | Conditions: Autoimmune Inner Ear Disease | Phase 2 | Status: COMPLETED